Loading…
Based on limited metadata, Kerry Inc received an FDA Warning Letter on July 26, 2018, regarding products classified outside the standard drug, device, or biologics categories. Without access to the full letter text or specific subject line details, the precise nature of the violations cannot be determined from the available information. The issuing office is not specified in the metadata provided. To understand the specific regulatory concerns and required corrective actions, review of the complete Warning Letter would be necessary.